Tags

Type your tag names separated by a space and hit enter

Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study.
Medicine (Baltimore). 2020 Mar; 99(12):e19276.M

Abstract

This study aimed to investigate the efficacy and safety of drug-eluting beads (DEB) transarterial chemoembolization (TACE) treatment in Chinese intrahepatic cholangiocarcinoma (ICC) patients.37 ICC patients underwent DEB-TACE treatment in CTILC study (registered on clinicaltrials.gov with registry No. NCT03317483) were included in this present study. Treatment response was assessed according to modified Response Evaluation Criteria in Solid Tumors (mRECIST). Overall survival (OS) was calculated from the time of DEB-TACE operation until the date of death from any causes. Liver function change and adverse events (AEs) were recorded during and after DEB-TACE operation.3 (8.1%) patients achieved complete response (CR) and 22 (59.5%) patients achieved partial response (PR), with objective response rate (ORR) of 67.6%. After DEB-TACE treatment, mean OS was 376 days (95%CI: 341-412 days). Multivariate logistic regression analysis revealed that Bilobar disease (P = .040, OR: 0.105, 95% CI: 0.012-0.898) and portal vein invasion (P = .038, OR: 0.104, 95% CI: 0.012-0.881) could independently predict less possibility of ORR. Patients with ALB abnormal, TP abnormal, ALT abnormal and AST abnormal were increased at 1-week post DEB-TACE treatment (P = .034, P = .001, P < .001, P = .006, respectively), while returned to the levels at baseline after 1 to 3 months (all P > .050). Besides, most of the AEs were mild including pain, fever, vomiting, and nausea in this study.DEB-TACE was effective and well tolerated in treating ICC patients, and bilobar disease as well as portal vein invasion were independently correlated with less probability of ORR achievement.

Authors+Show Affiliations

Department of Intervention, Zhejiang Cancer Hospital, Hangzhou.Department of Intervention, Zhejiang Cancer Hospital, Hangzhou.Department of Intervention, The Third Affiliated Hospital of Wenzhou Medical University, Ruian, China.Department of Hepatobiliary Surgery, Quzhou People's Hospital, Quzhou.Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou.Department of Hepatobiliary Surgery, Ningbo Medical Center, Lihuili Eastern Hospital, Ningbo.Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou.Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou.Department of Radiology, Beilun District People's Hospital of Ningbo, Ningbo.Department of Liver Oncology, Ningbo No.2 Hospital, Ningbo, China.Division of Digestive Endoscopy, Yueqing City People's Hospital, Yueqing.Department of Radiology, Xixi Hospital of Hangzhou, Hangzhou 6th People's Hospital, Hangzhou.Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou.Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou.Department of Intervention, Dong Yang people's Hospital, Dongyang.Interventional Center, Xinchang People's Hospital, Shaoxing.Department of Radiology, Shulan (Hangzhou) Hospital, Zhejiang University International Hospital, Hangzhou.Department of Radiology, Taizhou Hospital of Zhejiang Province, Linhai.Department of Intervention, Jiaxing First Hospital, Jiaxing.Department of Intervention, Jiaxing Second Hospital, Jiaxing.Department of Intervention, Jinhua Central Hospital, Jinhua.Department of Intervention, Zhejiang Cancer Hospital, Hangzhou.Department of Vascular and Interventional Radiology, The Affiliated Hospital of Medical College of Ningbo University, Ningbo.Department of Radiology, Hangzhou Cancer Hospital.Department of Intervention, Zhejiang Provincial People's Hospital, Hangzhou, China.Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou.Department of Liver Oncology, Ningbo No.2 Hospital, Ningbo, China.Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine, Hangzhou.Department of Intervention, Zhejiang Provincial People's Hospital, Hangzhou, China.Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine, Hangzhou.Department of Intervention, Zhejiang Cancer Hospital, Hangzhou.Department of Radiology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui.Department of Intervention, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Pub Type(s)

Journal Article
Multicenter Study
Observational Study

Language

eng

PubMed ID

32195932

Citation

Luo, Jun, et al. "Drug-eluting Beads Transarterial Chemoembolization By CalliSpheres Is Effective and Well Tolerated in Treating Intrahepatic Cholangiocarcinoma Patients: a Preliminary Result From CTILC Study." Medicine, vol. 99, no. 12, 2020, pp. e19276.
Luo J, Zheng J, Shi C, et al. Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study. Medicine (Baltimore). 2020;99(12):e19276.
Luo, J., Zheng, J., Shi, C., Fang, J., Peng, Z., Huang, J., Sun, J., Zhou, G., Li, T., Zhu, D., Xu, H., Hou, Q., Ying, S., Sun, Z., Du, H., Xie, X., Cao, G., Ji, W., Han, J., ... Hu, W. (2020). Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study. Medicine, 99(12), e19276. https://doi.org/10.1097/MD.0000000000019276
Luo J, et al. Drug-eluting Beads Transarterial Chemoembolization By CalliSpheres Is Effective and Well Tolerated in Treating Intrahepatic Cholangiocarcinoma Patients: a Preliminary Result From CTILC Study. Medicine (Baltimore). 2020;99(12):e19276. PubMed PMID: 32195932.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study. AU - Luo,Jun, AU - Zheng,Jiaping, AU - Shi,Changsheng, AU - Fang,Jian, AU - Peng,Zhiyi, AU - Huang,Jing, AU - Sun,Junhui, AU - Zhou,Guanhui, AU - Li,Tiefeng, AU - Zhu,Dedong, AU - Xu,Huanhai, AU - Hou,Qinming, AU - Ying,Shihong, AU - Sun,Zhichao, AU - Du,Haijun, AU - Xie,Xiaoxi, AU - Cao,Guohong, AU - Ji,Wenbin, AU - Han,Jun, AU - Gu,Wenjiang, AU - Guo,Xiaohua, AU - Shao,Guoliang, AU - Yu,Zhihai, AU - Zhou,Jian, AU - Yu,Wenqiang, AU - Zhang,Xin, AU - Li,Ling, AU - Hu,Hongjie, AU - Hu,Tingyang, AU - Wu,Xia, AU - Chen,Yutang, AU - Ji,Jiansong, AU - Hu,Wenhao, PY - 2020/3/21/entrez PY - 2020/3/21/pubmed PY - 2020/4/9/medline SP - e19276 EP - e19276 JF - Medicine JO - Medicine (Baltimore) VL - 99 IS - 12 N2 - This study aimed to investigate the efficacy and safety of drug-eluting beads (DEB) transarterial chemoembolization (TACE) treatment in Chinese intrahepatic cholangiocarcinoma (ICC) patients.37 ICC patients underwent DEB-TACE treatment in CTILC study (registered on clinicaltrials.gov with registry No. NCT03317483) were included in this present study. Treatment response was assessed according to modified Response Evaluation Criteria in Solid Tumors (mRECIST). Overall survival (OS) was calculated from the time of DEB-TACE operation until the date of death from any causes. Liver function change and adverse events (AEs) were recorded during and after DEB-TACE operation.3 (8.1%) patients achieved complete response (CR) and 22 (59.5%) patients achieved partial response (PR), with objective response rate (ORR) of 67.6%. After DEB-TACE treatment, mean OS was 376 days (95%CI: 341-412 days). Multivariate logistic regression analysis revealed that Bilobar disease (P = .040, OR: 0.105, 95% CI: 0.012-0.898) and portal vein invasion (P = .038, OR: 0.104, 95% CI: 0.012-0.881) could independently predict less possibility of ORR. Patients with ALB abnormal, TP abnormal, ALT abnormal and AST abnormal were increased at 1-week post DEB-TACE treatment (P = .034, P = .001, P < .001, P = .006, respectively), while returned to the levels at baseline after 1 to 3 months (all P > .050). Besides, most of the AEs were mild including pain, fever, vomiting, and nausea in this study.DEB-TACE was effective and well tolerated in treating ICC patients, and bilobar disease as well as portal vein invasion were independently correlated with less probability of ORR achievement. SN - 1536-5964 UR - https://www.unboundmedicine.com/medline/citation/32195932/Drug_eluting_beads_transarterial_chemoembolization_by_CalliSpheres_is_effective_and_well_tolerated_in_treating_intrahepatic_cholangiocarcinoma_patients:_A_preliminary_result_from_CTILC_study_ L2 - https://doi.org/10.1097/MD.0000000000019276 DB - PRIME DP - Unbound Medicine ER -